SCHEMBL2275760

SCHEMBL2275760

COC(=O)COc1ccc(/C=C/C(=O)c2c(O)cc(C)[nH]c2=O)cc1OC

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 2/20 0.61
ABCG2 Q9UNQ0 1/20 0.51
ALDH1A1 P00352 2/20 0.49
LMNA P02545 3/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
NPSR1 Q6W5P4 3/20 0.48
HTT P42858 2/20 0.48
MEN1 O00255 4/20 0.48
MAPT P10636 4/20 0.48
KMT2A Q03164 4/20 0.48
KDM4E B2RXH2 3/20 0.48
PDE4A P27815 2/20 0.48
PDE4B Q07343 2/20 0.48
PDE4C Q08493 2/20 0.48
PDE4D Q08499 2/20 0.48
PTGES O14684 2/20 0.48
SNCA P37840 1/20 0.47
FDPS P14324 1/20 0.47
CYP3A4 P08684 2/20 0.46
HPGD P15428 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2275766 1.00 APP (0.61) APPABCG2ALDH1A1LMNASMN1; SMN2
SCHEMBL2281911 0.91 APP (0.49) APPABCG2ALDH1A1LMNASMN1; SMN2
SCHEMBL2281909 0.91 APP (0.49) APPABCG2ALDH1A1LMNASMN1; SMN2
SCHEMBL2280074 0.89 APP (0.48) APPABCG2ALDH1A1LMNASMN1; SMN2
SCHEMBL2280070 0.89 APP (0.48) APPABCG2ALDH1A1LMNASMN1; SMN2
SCHEMBL2279826 0.86 LMNA (0.52) ABCG2LMNASMN1; SMN2NPSR1HTT
SCHEMBL2279822 0.86 LMNA (0.52) ABCG2LMNASMN1; SMN2NPSR1HTT
SCHEMBL2279958 0.83 ABCG2 (0.48) APPABCG2ALDH1A1LMNASMN1; SMN2
SCHEMBL2279961 0.83 ABCG2 (0.48) APPABCG2ALDH1A1LMNASMN1; SMN2
SCHEMBL16488002 0.77 APP (1.00) APPABCG2ALDH1A1LMNANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989478-B2 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-02 US disclosed
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-09-21 US disclosed
EP-1671948-A1 CINNAMOYL COMPOUND AND USE OF THE SAME Sumitomo Chemical Company, Limited (JP) 2006-06-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis COL2A1, COL1A1, COL14A1 APP 3864/4885ABCG2 4878/4885ALDH1A1 576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.